Market closedNon-fractional

Outlook Therapeutics/OTLK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Outlook Therapeutics

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Ticker

OTLK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Iselin, United States

Employees

24

OTLK Metrics

BasicAdvanced
$171M
Market cap
-
P/E ratio
-$11.98
EPS
0.28
Beta
-
Dividend rate
$171M
0.28
1.069
0.873
-33.333
-27.28%
-66.19%
257.19%
-1.22
-1.22
-1.669
142.25%
21.47%

What the Analysts think about OTLK

Analyst Ratings

Majority rating from 7 analysts.
Buy

OTLK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$114M
928.83%
Profit margin
0.00%
NaN%

OTLK Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 842.35%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$1.60
-$1.00
-$0.80
-$8.01
-
Expected
-$1.03
-$1.18
-$1.00
-$0.85
-$1.02
Surprise
55.56%
-14.89%
-20.00%
842.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Outlook Therapeutics stock?

Outlook Therapeutics (OTLK) has a market cap of $171M as of July 06, 2024.

What is the P/E ratio for Outlook Therapeutics stock?

The price to earnings (P/E) ratio for Outlook Therapeutics (OTLK) stock is 0 as of July 06, 2024.

Does Outlook Therapeutics stock pay dividends?

No, Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Outlook Therapeutics dividend payment date?

Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders.

What is the beta indicator for Outlook Therapeutics?

Outlook Therapeutics (OTLK) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Outlook Therapeutics stock

Buy or sell Outlook Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing